Pharmafile Logo

Keytruda

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Keytruda in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Keytruda.

1

Global Revenue Ranking

5

2030 Global forecast Ranking

Recent articles on PMLiVE featuring Keytruda

- PMLiVE
Pfizer’s PADCEV gets FDA approval for bladder cancer

Bladder cancer affects more than 614,000 people globally each year

- PMLiVE
MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

- PMLiVE
Merck unveils $3bn cost-cutting plan to support pipeline and new product launches

A new restructuring programme has been approved to support the initiative

- PMLiVE
ASCO 2025 – bringing a sense of urgency to the war against cancer

‘Hot’ tumours, breast cancer breakthroughs and holistic treatment were the standouts at this year’s event

- PMLiVE
Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer

More than 72,680 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE
Merck shares promising phase 3 results for Keytruda in ovarian cancer

Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year

- PMLiVE
Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

- PMLiVE
Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer

Approximately 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE
Pfizer shares positive late-stage results for sasanlimab combination in bladder cancer

Approximately 10,500 people are diagnosed with bladder cancer in the UK every year

- PMLiVE
Merck shares positive phase 3 results for Keytruda/Lynparza regimen in ovarian cancer

Ovarian cancer is the seventh most common cancer in women globally

- PMLiVE
Merck’s Keytruda recommended by NICE to reduce risk of lung cancer recurrence

More than 5,000 patients in England are expected to be eligible for the anti-PD-1 therapy

- PMLiVE
Merck and Exelixis partner to evaluate new cancer combination treatments

The companies will evaluate the regimens in head and neck cancer and renal cell carcinoma

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links